Evaluating a Treatment for HER2-Positive Metastatic Breast Cancer
Manage episode 388480997 series 3334765
ReachMD에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 ReachMD 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Host: Pavani Chalasani, MD, MPH
Guest: Erika Hamilton, MD
A new treatment option for breast cancer may alter the treatment landscape for patients with HER2-positive metastatic breast cancer. Joining Dr. Pavani Chalasani to share data from the DESTINY Breast03 trial is Dr. Erika Hamilton, the Director of the Breast Cancer and Gynecologic Cancer Research Program at Sarah Cannon Research Institute at Tennessee Oncology.
…
continue reading
Guest: Erika Hamilton, MD
A new treatment option for breast cancer may alter the treatment landscape for patients with HER2-positive metastatic breast cancer. Joining Dr. Pavani Chalasani to share data from the DESTINY Breast03 trial is Dr. Erika Hamilton, the Director of the Breast Cancer and Gynecologic Cancer Research Program at Sarah Cannon Research Institute at Tennessee Oncology.
122 에피소드